Evidence map›Paper›PMID 40578905›Full record

Observational studyBMJ open ophthalmology2025

The real-world effectiveness of defocus incorporated multiple segments and highly aspherical lenslets on myopia control: a longitudinal study from the French myopia cohort.

Rime Najji, Mark Bullimore, Serge Resnikoff, Alain M Bron, Mathieu Naudin, Clément Giraud, Rupert Bourne, Jost B Jonas, Nicolas Leveziel

Abstract readObservational StudyComparative StudyMulticenter Study
In one paragraph

Observational study in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rime NajjiLabCom CNRS I3M, Siemens Healthineers - University of Poitiers and CHU Poitiers, Poitiers, France.ORCID 0009-0007-0345-7857
Mark BullimoreCollege of Optometry, University of Houston, Houston, Texas, USA.
Serge ResnikoffBrien Holden Vision Institute, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-5866-4446
Alain M BronDepartment of Ophthalmology, CHU Dijon Bourgogne, Dijon, France.ORCID 0000-0002-7265-931X
Mathieu NaudinLabCom CNRS I3M, Siemens Healthineers - University of Poitiers and CHU Poitiers, Poitiers, France.
Clément GiraudLabCom CNRS I3M, Siemens Healthineers - University of Poitiers and CHU Poitiers, Poitiers, France.
Rupert BourneVision and Eye research Institute, Cambridge, UK.
Jost B JonasInstitut Français de Myopie, Hôpital Fondation Adolphe de Rothschild, Paris, France.
Nicolas LevezielLabCom CNRS I3M, Siemens Healthineers - University of Poitiers and CHU Poitiers, Poitiers, France nicolas.leveziel@yahoo.fr.ORCID 0000-0001-8533-9457

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the efficacy of myopia control by spectacle lenses in a real-world study.

methodsThis is a longitudinal, retrospective, comparative, observational, real-world study of the French Myopia Cohort. Records of prescriptions for optical correction, gender and age were collected from 1500 opticians between 2020 and 2023. The study cohort consisted of myopic children aged 4 to 15 years who were assigned to three groups: two control groups wearing single vision lenses (SVL) and one intervention group wearing myopia control spectacles (MCS); either defocus incorporated multiple segments (DIMS, n=1786) or highly aspheric lenses (HAL, n=585). The first SVL group was matched to the MCS group for age, sex and initial refractive error (first matching), and the second SVL group was matched for the same criteria and myopia progression during the first 6 months of follow-up (second matching).The difference in myopia progression was calculated between SVL groups and the MCS group. DIMS and HAL were also compared for myopia progression.

resultsA total of 2542 children (mean age of 9.5 years and mean spherical equivalent of -2.3 D at baseline) were included in each of the three groups. The mean progression rates for MCS were by +0.59 D (95% CI +0.57 to +0.62D; p<0.001) after the first matching and by +0.30 D (95% CI +0.28 to +0.32D; p<0.001) after the second matching, in comparison to the SVL groups. Children wearing HAL spectacles showed slightly less myopia progression (difference in progression = +0.14 D, 95% CI = +0.10 to +0.18, p<0.001) compared with the DIMS group.

conclusionsAlthough there are some limitations, including its retrospective design, the lack of lifestyle and environmental data and the use of SE rather than axial length, this study showed that in a real-world setting, both DIMS and HAL spectacles demonstrated efficacy in reducing myopia progression. While a statistically significant lower myopia progression rate was observed in the HAL group, this difference was not clinically meaningful. This study also showed that DIMS and HAL reduce myopia progression among younger children aged 4 to 6 years.

Indexed as

EyeglassesMyopiaRefraction, OcularVisual AcuityAdolescentChildChild, PreschoolDisease ProgressionFemaleFollow-Up StudiesFranceHumansLongitudinal StudiesMaleRetrospective StudiesTreatment OutcomeChild health (paediatrics)Optics and RefractionTreatment MedicalVision

Identifiers

PMID40578905
PMCPMC12207109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.